Protagonist Therapeutics PTGX
NASDAQ PTGX
$134.86 -1.40 (-1.03%)
At close: Nov 11, 2026 · 4:00 PM EST

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2017)

Updated

Protagonist Therapeutics (PTGX) posted Gains from Sales and Divestitures of -$8,000 for FY2019.

Analysis

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2017) Analysis & Trends

  • The FY2019 figure stands as the lowest annual Gains from Sales and Divestitures since FY2016.
  • Business Quant data shows PTGX's Gains from Sales and Divestitures at $62,000 in FY2017 and -$34,000 in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Protagonist Therapeutics 8.89 Bn 6.19 Bn 273.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 -3,000.00
API Access

Protagonist Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PTGX&period=max&api_key=YOUR_API_KEY